A Mayo Clinic retrospective study presented at the 2025 Annual Meeting of The Menopause Society found that postmenopausal women using menopausal hormone therapy (MHT) achieved the greatest weight loss with tirzepatide compared with other reproductive-stage groups. Among 160 women treated for obesity (mean age 50 years; body mass index 34 kg/m²), postmenopausal women receiving MHT lost an average of 19.9% of total body weight versus 15.6% among postmenopausal women not on MHT, while premenopausal and perimenopausal women achieved similar reductions of about 18.6% to 18.7%. Using propensity-score matching to control for diabetes and prior weight-loss drug use, researchers reported consistent efficacy across reproductive stages, suggesting MHT may enhance tirzepatide’s metabolic and weight-loss benefits in postmenopausal women.

Source: 2025 Annual Meeting of The Menopause Society